Physician profile

Eduardo Andre

Pulmonary Disease · Pembroke Pines, FL

NPI 1548606437

$2,736.17

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$46.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $912.07 2019-2024 Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals Lp $462.66 2019-2021
Genentech USA, INC. $308.49 2019
Boehringer Ingelheim Pharmaceuticals, INC. $198.37 2019-2020
Regeneron Healthcare Solutions, INC. $124.52 2021
Resmed Corp $121.49 2022-2024
Grifols USA, LLC $110.47 2019-2021
Sunovion Pharmaceuticals INC. $109.01 2019-2021
Philips North America LLC $92.07 2019-2020
Circassia INC. $65.89 2019
Mylan Specialty L.P. $63.92 2019
Actelion Pharmaceuticals US, INC. $47.19 2019
Shire North American Group INC $36.36 2019
Horizon Therapeutics Plc $19.07 2019
Electromed, INC. $17.30 2019
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $16.74 2019
Takeda Pharmaceuticals U.S.A., INC. $15.48 2020
Janssen Pharmaceuticals, INC $15.07 2019

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$143.29 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eduardo Andre

$2,736.17

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/70368/eduardo-andre

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.